| Therapeutic | Utomilumab |
| Target | TNFRSF9 |
| Heavy Chain | EVQLVQSGAEVKKPGESLRISCKGSGYSFSTYWISWVRQMPGKGLEWMGKIYPGDSYTNYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGYGIFDYWGQGTLVTVSS |
| Light Chain | SYELTQPPSVSVSPGQTASITCSGDNIGDQYAHWYQQKPGQSPVLVIYQDKNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYTGFGSLAVFGGGTKLTVL |
| 100% seqID Fv Structure | 6a3w [Fvs: AB, DE, GH, JK], 6mi2 [Fvs: AB, DE] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 6a3w [Fvs: AB, DE, GH, JK] |
| 100% seqID Structure | 6mi2 [Fvs: AB, DE] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G2 |
| Highest Clinical Trial (Feb '25) | Phase-II |
| Estimated Status (Feb '25) | Active |
| Recorded Developmental Technology | MorphoSys HuCAL Phage Display |
| INN Year Proposed | 2016 |
| INN Year Recommended | 2017 |
| Companies Involved | Dana-Farber Cancer Institute, Immatics US, Kite Pharma, Kyowa Hakko Kirin, M. D. Anderson Cancer Center, Pfizer |
| Conditions Approved | na |
| Conditions Active | Breast cancer, Oropharyngeal cancer, Solid tumours, B-cell lymphoma, Diffuse large B cell lymphoma, Colorectal cancer, Follicular lymphoma, Ovarian cancer |
| Conditions Discontinued | Non-Hodgkin's lymphoma |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
